By 2030, it is anticipated that the UAE infectious disease therapeutics market will reach a value of $909.4 Mn from $599.35 Mn in 2022, growing at a CAGR of 5.4% during 2022-2030. The Infectious Disease Therapeutics in UAE is dominated by a few domestic pharmaceutical companies such as Medpharma, Julphar and Neopharma. The Infectious Disease Therapeutics market in UAE is segmented into different therapeutic areas and different diseases type. The major factors affecting the UAE infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various the areas of UAE.
By 2030, it is anticipated that the UAE infectious disease therapeutics market will reach a value of $909.4 Mn from $599.35 Mn in 2022, growing at a CAGR of 5.4% during 2022-2030.
United Arab Emirates (UAE) is a high-income, developing country located in the Middle East bordering the Gulf of Oman and the Persian Gulf. A variety of factors influence the use of infectious disease medications in the UAE, including disease prevalence, prescribing practices, and public health policy. The UAE government has taken initiatives to address challenges such as antibiotic resistance and developing infectious diseases, but more work is needed to ensure that infectious disease medications are used appropriately.
Pharmaceutical companies such as Pfizer, Moderna, AstraZeneca, and Johnson & Johnson have also been approved for emergency use in the UAE, which is helping to drive the infectious disease industry forward. When compared to its neighbours, the UAE has a higher level of economic diversification. UAE's government spends 5.5% of its GDP on healthcare.
Market Growth Drivers Analysis
Antibiotic resistance is a major concern in the UAE, and the government has taken several steps to address it, including promoting prudent antibiotic use and eliminating needless prescribing. Infectious disorders such as hepatitis, TB, and HIV/AIDS are becoming more common in the UAE. As a result, there is an increasing demand for effective therapies for these disorders. The UAE has a comparatively high per capita healthcare spending, owing to the country's growing population and the increasing frequency of chronic and infectious diseases. For enterprises, the UAE is an excellent regional trading hub. These aspects could boost UAE infectious disease therapeutics market.
Market Restraints
Alternative pharmaceutical companies, as well as other treatment approaches such as vaccinations and antibiotics, frequently dominate the infectious disease therapeutics market in the UAE. The UAE government regulates medicine costs, which can limit what pharmaceutical companies can charge for infectious disease therapies and have an impact on profitability. Access to some infectious disease medicines in the UAE may be restricted by rules such as prescribing limitations or prior authorisation requirements. These factors may deter new entrants into the UAE infectious disease therapeutics market.
Key Players
April 2022: Gulf Pharmaceutical Industries: Julphar, one of the Middle East and Africa's major pharmaceutical businesses, has launched its Strategy 2030 to accelerate transformation through sustainable growth and deliver greater value to all stakeholders. The news came after the company successfully completed one of the region's most amazing turnaround tales, indicating a return to profit in 2021 with substantial top-line growth. Strategy 2030 is aimed to treble Julphar's revenues via six primary growth pillars - "Maximizing Revenue from present Product Portfolio" "New Product Launches," "Geographical Expansions," "Strategic Business Initiatives,", "Advanced Specialty Products Initiative", and "In-Organic Growth Initiatives".
The Ministry of Health and Prevention (MOHAP) and health insurance providers are largely responsible for the regulation and reimbursement of infectious disease medicines in the United Arab Emirates (UAE). Furthermore, certain coverage limitations, including co-payments or deductibles, may affect patients' out-of-pocket costs.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.